Challenges in RAS Wild-Type mCRC

Introduction

Decision-Making Algorithm for First-Line Treatment of mCRC

Clinical Utility of ctDNA

Treatment of mCRC: ESMO Guidelines

First-Line Treatment for Right-Sided Tumors

First-Line Treatment: Patient Preferences

Optimal Treatment Choices for Disease Control by Location of Primary Tumor*

CRYSTAL and FIRE-3 Trials

Second-Line Therapy for mCRC

Mechanisms of Resistance to Anti-EGFR Pathways

Cetuximab Beyond Progression: CAPRI GOIM Study PFS According to KRAS, NRAS, BRAF, and PIK3CA Status

Continuation/Maintenance With Anti-EGFR Treatment Involves Managing Toxicity Profiles

Retest for RAS?

Tailoring the Treatment Strategy to Patient and Tumor Characteristics

ASPECCT Trial: OS and PFS Results Patients With Prior Bevacizumab Treatment in Chemorefractory wtKRAS exon 2 mCRC

Bevacizumab Followed by Anti-EGFR Therapy: Unanswered Questions

Cetuximab Rechallenge: Rationale (Santini Hypothesis)

Time From Last Treatment With EGFR mAbs Correlates With Quantification of KRAS Mutations Detected in ctDNA

Strategies to Address Mechanisms of Resistance

CRICKET Study: Good Response to Cetuximab Rechallenge in Irinotecan‑Refractory mCRC

Rechallenge With Anti-EGFR Therapy: FIRE-4 Study

Key Points of Studies Using Rechallenge With Anti-EGFR

Determining Wash-Out Periods

Monitoring for Resistance Using Liquid Biopsy May Allow Timely Decision Making

Conclusions

Abbreviations

Abbreviations (cont)